

Prescribing Safely and Ethically to Children and Adolescents	2	NMDA Receptor Antagonist	125	Comparison of Anticonvulsants	322
Psychiatric Disorders in Children and Adolescents	4	Effects of Antidepressants on Neurotransmitters/ Receptors	128	Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses	330
NEURODEVELOPMENTAL DISORDERS	5	Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors	129	Substances of Abuse	333
Autism Spectrum Disorder (ASD)	5	Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses	130	Alcohol	336
Attention-Deficit/Hyperactivity Disorder (ADHD)	6	Antidepressant Doses and Pharmacokinetics	133	Stimulants	341
Tourette's Disorder	7	Switching Antidepressants	137	Hallucinogens	347
SCHIZOPHRENIA	8	Antidepressant Augmentation Strategies	139	Opioids	356
BIPOLAR DISORDER (BD)	10	Electroconvulsive Therapy (ECT)	145	Inhalants/Aerosols	361
DEPRESSIVE DISORDERS	11	Antipsychotics	152	Sodium Oxybate (Gamma-Hydroxybutyrate – GHB)	363
Disruptive Mood Dysregulation Disorder (DMDD)	11	First-Generation Antipsychotics (FGAs)	158	Flunitrazepam (Rohypnol)	365
Major Depressive Disorder (MDD)	12	Second-Generation Antipsychotics (SGAs)	175	Nicotine/Tobacco	366
ANXIETY DISORDERS	13	Third-Generation Antipsychotics (TGAs)	206	Treatment of Substance Use Disorders	370
Separation Anxiety Disorder	14	Effects of Antipsychotics on Neurotransmitters/Receptors	217	Acamprosate	371
Specific Phobia	14	Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptor Subtypes	218	Disulfiram	373
Social Anxiety Disorder	15	Frequency (%) of Adverse Reactions to Antipsychotics at Therapeutic Doses	219	Naltrexone	376
Panic Disorder	16	Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections)	221	Buprenorphine	380
Generalized Anxiety Disorder (GAD)	17	Comparison of Long-Acting IM Antipsychotics	228	Methadone	384
OBSESSIVE-COMPULSIVE DISORDER (OCD)	18	Switching Antipsychotics	233	Pharmacotherapy for Nicotine/Tobacco Use Dependence	390
POSTTRAUMATIC STRESS DISORDER (PTSD)	19	Antipsychotic Augmentation Strategies	235	Comparison of Treatments for Nicotine/Tobacco Use Disorder	392
DISRUPTIVE, IMPULSE-CONTROL, AND CONDUCT DISORDERS	20	Antipsychotic-Induced Extrapyramidal Side Effects (EPSE) and Their Management	242	Unapproved Treatments of Psychiatric Disorders	397
Oppositional Defiant Disorder (ODD)	20	Extrapyramidal Side Effects of Antipsychotics	242	Adrenergic Agents	398
Conduct Disorder (CD)	20	Treatment Options for Extrapyramidal Side Effects	249	Anti-inflammatory Agents	399
SYNDROME: Catatonia	21	Effects on Extrapyramidal Side Effects	255	Cholinergic Agents	400
Drugs for ADHD	25	Comparison of Agents for Treating Acute Extrapyramidal Side Effects	256	Dopaminergic Agents	401
Psychostimulants	25	Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal Side Effects	258	NMDA Agents	402
Selective Norepinephrine Reuptake Inhibitors	36	Anxiolytic (Antianxiety) Agents	263	Miscellaneous	405
Comparison of Drugs for ADHD	41	Benzodiazepines	263	Natural Health Products	406
α ₂ agonists	46	Comparison of the Benzodiazepines	272	Pharmacogenetic Information for Common Psychotropic Drugs	418
Augmentation Strategies in ADHD	49	Buspirone	277	Genotype Effects on Pharmacokinetic Properties of Psychotropic Drugs	418
Antidepressants	52	Hypnotics/Sedatives	282	Pharmacogenomics-Based Dose Adjustment Recommendations and Guidelines	419
Selective Serotonin Reuptake Inhibitors (SSRIs)	53	Comparison of Hypnotics/Sedatives	289	Management of Aggression in Children and Adolescents	422
Norepinephrine Dopamine Reuptake Inhibitor (NDRI)	67	Mood Stabilizers	296	Glossary	424
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)	73	Lithium	296	Drug Use in Pregnancy and Effects on Breast Milk	428
Serotonin-2 Antagonists/Reuptake Inhibitors (SARIs)	81	Anticonvulsants	305	Patient and Caregiver Information Sheets	429
Serotonin-1A Partial Agonist/Serotonin Reuptake Inhibitor (SPARI)	88			Index of Drugs	430
Serotonin Modulator and Stimulator (SMS)	92				
Noradrenergic/Specific Serotonergic Antidepressant (NaSSA)	97				
Nonselective Cyclic Antidepressants	102				
Monoamine Oxidase Inhibitors	111				
Reversible Inhibitor of MAO-A (RIMA)	112				
Irreversible Monoamine Oxidase (A&B) Inhibitors (MAOIs)	115				
Irreversible MAO-B Inhibitor	122				